A Review of the Epidemiology and the Mechanisms Underlying KSHV‐induced Malignancies

Khaled R Alkharsah, Institute of Virology, Hannover, Germany
Thomas F Schulz, Institute of Virology, Hannover, Germany
Magdalena M Weidner‐Glunde, Institute of Virology, Hannover, Germany

Published online: March 2009

DOI: 10.1002/9780470015902.a0021547

Kaposi's sarcoma herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8), is believed to be the infectious causative agent of Kaposi's sarcoma and two other rare acquired immune deficiency syndrome (AIDS)-associated neoplastic diseases. KSHV is relatively frequent in some countries of the Mediterranean area, and quite common in sub-Saharan and South Africa, but rare in most other parts of the world. The virus is transmitted through sexual contact among adults. However, in endemic countries, the mode of transmission is most probably via behavioural practices using saliva from mother to child and between siblings. KSHV persists in infected cells in a latent episomal form expressing only a small number of genes to escape immune surveillance. These genes play a significant role in viral persistence and development of malignancy. A small number of KSHV-infected cells undergo spontaneous lytic reactivation to ensure the production of new virions and provide inflammatory cytokines that participate in development of cancer.

Key concepts:

  • KSHV is a 2-herpesvirus (Rhadinovirus) that causes Kaposi sarcoma, Primary effusion lymphoma and Multicentric Castleman's disease mainly in immunocompromised individuals, e.g. AIDS patients.
  • Similarly to the other herpesviruses KSHV has two phases of replication, latent and lytic.
  • In malignancies, the virus is detected mainly in latent state, where only few proteins are expressed.
  • Small number of infected cells undergo spontaneous lytic reactivation producing both, new virions for infecting new cells and inflammatory cytokines, which contribute to tumourigenesis through a paracrine mechanism.
  • KSHV expresses several genes that play a role in inhibition of apoptosis (vFLIP, vBCL2), progression of cell cycle (vCYC, LANA), stimulation of cytokine production and angiogenesis (vGPCR, vFLIP, vIL-6, K15).
  • The prevalence of KSHV is low in most parts of the world, but higher in Mediterranean area and highest in Africa.
  • KSHV-induced malignancies are rare even in areas with high KSHV prevalence.
  • KSHV is transmitted mainly by sexual contact among adults and via behavioural practices using saliva from mother to child and between siblings in endemic countries.

Keywords: KSHV/HHV-8; Kaposi's sarcoma; epidemiology; virus-induced malignancy; cytokine secretion

Figure 1. Apoptosis inhibitors encoded by KSHV. KSHV encoded proteins inhibit programmed cell death by blocking different pathways at many levels.
Figure 2. Mitogenic proteins of KSHV. Both viral latent proteins (e.g. LANA) as well as lytic proteins (e.g. vIL-6) disregulate the G1/S transition point of the cell cycle.
close
 References
    Ablashi DV, Chatlynne LG, Whitman JE Jr and Cesarman E (2002) Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clinical Microbiological Review 15: 439–464.
    Alkharsah KR, Dedicoat M, Blasczyk R, Newton R and Schulz TF (2007) Influence of HLA alleles on shedding of Kaposi sarcoma-associated herpesvirus in saliva in an African population. Journal of Infectious Diseases 195: 809–816.
    An J, Sun Y, Sun R and Rettig MB (2003) Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 22: 3371–3385.
    Andreoni M, Sarmati L, Nicastri E et al. (2002) Primary human herpesvirus 8 infection in immunocompetent children. JAMA 287: 1295–1300.
    Bajaj BG, Verma SC, Lan K et al. (2006) KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology 351: 18–28.
    Brinkmann MM, Pietrek M, Dittrich-Breiholz O, Kracht M and Schulz TF (2007) Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus. Journal of Virology 81: 42–58.
    Brinkmann MM and Schulz TF (2006) Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. Journal of General Virology 87: 1047–1074.
    Brown EE, Fallin MD, Goedert JJ et al. (2005) A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiology, Biomarkers & Prevention 14: 633–637.
    Bubman D, Guasparri I and Cesarman E (2007) Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26: 4979–4986.
    Carbone A and Gaidano G (1997) HHV-8-positive body-cavity-based lymphoma: a novel lymphoma entity. British Journal of Haematology 97: 515–522.
    Cesarman E, Chang Y, Moore PS, Said JW and Knowles DM (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New England Journal of Medicine 332: 1186–1191.
    Chang Y, Cesarman E, Pessin MS et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
    Chen YB, Rahemtullah A and Hochberg E (2007) Primary effusion lymphoma. Oncologist 12: 569–576.
    Chugh P, Matta H, Schamus S et al. (2005) Constitutive NF-kappaB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proceedings of the National Academy of Sciences of the USA 102: 12885–12890.
    Coluzzi M, Calabro ML, Manno D et al. (2003) Reduced seroprevalence of Kaposi's sarcoma-associated herpesvirus (KSHV), human herpesvirus 8 (HHV8), related to suppression of Anopheles density in Italy. Medical and Veterinary Entomology 17: 461–464.
    Damania B, Choi JK and Jung JU (2000) Signaling activities of gammaherpesvirus membrane proteins. Journal of Virology 74: 1593–1601.
    Dedicoat M and Newton R (2003) Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. British Journal of Cancer 88: 1–3.
    Dedicoat M, Newton R, Alkharsah KR et al. (2004) Mother-to-child transmission of human herpesvirus-8 in South Africa. Journal of Infectious Diseases 190: 1068–1075.
    Di Bartolo DL, Cannon M, Liu YF et al. (2008) KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood 111: 4731–4740.
    Dilnur P, Katano H, Wang ZH et al. (2001) Classic type of Kaposi's sarcoma and human herpesvirus 8 infection in Xinjiang, China. Pathology International 51: 845–852.
    Direkze S and Laman H (2004) Regulation of growth signalling and cell cycle by Kaposi's sarcoma-associated herpesvirus genes. International Journal of Experimental Pathology 85: 305–319.
    Dukers NH and Rezza G (2003) Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 17: 1717–1730.
    Ganem D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annual Reviews in Pathology 1: 273–296.
    Guttman-Yassky E, Cohen A, Kra-Oz Z et al. (2004) Familial clustering of classic Kaposi sarcoma. Journal of Infectious Diseases 189: 2023–2026.
    Jarviluoma A and Ojala PM (2006) Cell signaling pathways engaged by KSHV. Biochimica et Biophysica Acta 1766: 140–158.
    Lan K, Verma SC, Murakami M et al. (2007) Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein. Proceedings of the National Academy of Sciences of the USA 104: 16287–16292.
    Liu J, Martin HJ, Liao G and Hayward SD (2007) The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. Journal of Virology 81: 10451–10459.
    Lubyova B, Kellum MJ, Frisancho JA and Pitha PM (2007) Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. Journal of Biological Chemistry 282: 31944–31953.
    Martin MJ, Tanos T, Garcia AB et al. (2007) The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis. Journal of Biological Chemistry 282: 34510–34524.
    Matta H, Mazzacurati L, Schamus S et al. (2007) Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation. Journal of Biological Chemistry 282: 24858–24865.
    Mohanna S, Maco V, Bravo F and Gotuzzo E (2005) Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: a critical review of an old disease. International Journal of Infectious Diseases 9: 239–250.
    Montaner S (2007) Akt/TSC/mTOR activation by the KSHV G protein-coupled receptor: emerging insights into the molecular oncogenesis and treatment of Kaposi's sarcoma. Cell Cycle 6: 438–443.
    Moore PS and Chang Y (2001) Molecular virology of Kaposi's sarcoma-associated herpesvirus. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 356: 499–516.
    Murakami Y, Yamagoe S, Noguchi K et al. (2006) Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx. Journal of Biological Chemistry 281: 28113–28121.
    Nicholas J (2007) Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia. Frontiers in Bioscience 12: 265–281.
    Ottinger M, Christalla T, Nathan K et al. (2006) Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4–and BRD2/RING3-induced G1 cell cycle arrest. Journal of Virology 80: 10772–10786.
    Schulz TF (1999) Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. Advances in Cancer Research 76: 121–160.
    Schulz TF (2006) The pleiotropic effects of Kaposi's sarcoma herpesvirus. Journal of Pathology 208: 187–198.
    Schwartz RA, Micali G, Nasca MR and Scuderi L (2008) Kaposi sarcoma: a continuing conundrum. Journal of the American Academy of Dermatology 59: 179–206.
    Seo T, Lee D, Shim YS et al. (2002) Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM19, and inhibits interferon/retinoic acid-induced cell death. Journal of Virology 76: 8797–8807.
    Seo T, Park J and Choe J (2005) Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Research 65: 1738–1747.
    Serraino D, Cerimele D, Piselli P et al. (2006) Infection with human herpesvirus type 8 and Kaposi's sarcoma in Sardinia. Infection 34: 39–42.
    Soulier J, Grollet L, Oksenhendler E et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
    Thome M, Schneider P, Hofmann K et al. (1997) Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517–521.
    Tomlinson CC and Damania B (2004) The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. Journal of Virology 78: 1918–1927.
    Vart RJ, Nikitenko LL, Lagos D et al. (2007) Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Research 67: 4042–4051.
    Viejo-Borbolla A and Schulz TF (2003) Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis. AIDS Review 5: 222–229.
    Whitby D, Marshall VA, Bagni RK et al. (2007) Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. International Journal of Cancer 120: 321–328.
    Wojcicki JM, Newton R, Urban M et al. (2004) Low socioeconomic status and risk for infection with human herpesvirus 8 among HIV-1 negative, South African black cancer patients. Epidemiology and Infection 132: 1191–1197.
 Further reading
    Barozzi P, Potenza L, Riva G et al. (2007) B cells and herpesviruses: a model of lymphoproliferation. Autoimmunity Reviews 7(2): 132–136.
    Du M-Q, Bacon CM and Isaacson PG (2007) Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. Journal of Clinical Pathology 60(12): 1350–1357.
    book Flint SJ, Enquist LW, Krug RM, Racaniello VR and Skalka AM (2000) Principles of Virology. Washington, DC: ASM Press.
    book Knipe DM, Howley PM and Griffin DE (2007) Field's Virology. 5th edn. Philadelphia: Lippincott Williams & Wilkins.
    book Viejo-Borbolla A, Henke-Gendo C and Schulz TF (2004) "Kaposi's sarcoma associated herpesvirus (Human Herpesvirus 8)" In: Zukerman AJ, Banatvala JE, Pattison JR, Griffiths PD and Schoub BD (eds) Principles and Practice of Clinical Virology. 5th edn. pp. 169–198. England: Wiley.

Related Sub-Topics:

Virus Diseases | DNA Viruses | Viruses Infecting Humans | Cell Biology of Cancer
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: A Review of the Epidemiology and the Mechanisms Underlying KSHV‐induced Malignancies
 
How to Cite close
Alkharsah, Khaled R, Schulz, Thomas F, and Weidner‐Glunde, Magdalena M(Mar 2009) A Review of the Epidemiology and the Mechanisms Underlying KSHV‐induced Malignancies. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0021547]